Kazazian Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History

Kazazian Asset Management’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-9,021	Closed	-$326K	–	71
2018 Q4	$326K	Sell	9,021 -5,496	-38%	-$258K	0.44%	42
2018 Q3	$894K	Sell	14,517 -3,133	-18%	-$201K	0.84%	32
2018 Q2	$1.19M	Sell	17,650 -671	-4%	-$37.5K	1.09%	25
2018 Q1	$994K	Buy	18,321 +5,855	+47%	+$327K	1.04%	26
2017 Q4	$745K	Sell	12,466 -2,111	-14%	-$128K	0.76%	32
2017 Q3	$708K	Buy	14,577 +6,019	+70%	+$328K	0.87%	28
2017 Q2	$450K	Buy	+8,558	New	+$398K	0.68%	29

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Kazazian Asset Management's AERI Position: Q1 2019 in Review

Kazazian Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q1 2019, closing a stake of 9,021 shares — an estimated $326K sold.

Kazazian Asset Management first reported a position in AERI in Q2 2017 and held it in 7 quarters. The position peaked at $1.19M in Q2 2018. 176 funds tracked by Wall St. Rank hold AERI as of Q1 2019.

Kazazian Asset Management reported no remaining Aerie Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Kazazian Asset Management sold 9,021 Aerie Pharmaceuticals shares in Q1 2019, an estimated $326K.
Kazazian Asset Management first reported a position in Aerie Pharmaceuticals in Q2 2017 and held it in 7 quarters.
Kazazian Asset Management's Aerie Pharmaceuticals position peaked at $1.19M in Q2 2018.
176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q1 2019.

Based on Kazazian Asset Management's 13F filing for Q1 2019, filed 15 May 2019.